Pre-clinical mechanism
Non-peptide GHS-R1a agonist that elevates GH and IGF-1 in animal and human pharmacology with a long oral half-life relative to peptide secretagogues.
Key pre-clinical findings
- Two-year healthy older-adult study: sustained increases in fat-free mass and IGF-1 versus placebo (Nass et al., 2008).
Primary literature
Research and educational use only. This page summarises publicly available pre-clinical literature for educational and scientific reference. It is not medical, clinical, dosing or therapeutic advice. Nothing on this page implies that any VCP Australia product is approved, certified, safe, effective, suitable for a particular purpose, or intended for human or animal consumption.